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ABSTRACT 
Introduction: Deep Brain stimulation of the globus pallidus can be a highly effective treatment 
for patients with Parkinson’s disease (PD), experiencing Levodopa-induced-dyskinesia (LID). 
Stimulation programming can focus simply on eliminating dyskinesia, or can also attempt to 
relieve the rigidity, tremor or akinesia of PD itself. 
 
Methods: In this study, we explored whether additional benefit on the “off” symptoms and 
signs of PD, could be achieved in post-operative PD patients with good LID control, by 
making further adjustment to existing stimulation parameters directed towards the more 
superior electrode contacts, located in the Globus Pallidus pars externa (GPe). 
 
Results: Acutely, GPe-DBS led to clear improvement in the akinesia, rigidity and tremor of 
PD in the off-medication state compared with Globus Pallidus pars interna (GPi) DBS 
(p=0.003), however this was accompanied by the development of off-medication dyskinesia. 
Combined GPi-GPe DBS allowed maintained improvement but without dyskinesia. Follow up 
of patients over the subsequent 6-12 weeks showed gradual loss of this initial improvement. 
Switching back to GPi-DBS alone provided greater improvement in off medication symptoms 
than had been observed using the same GPi-DBS setting, 6-12 weeks previously. 
 
Conclusions: Benefits on the off-medication symptoms of PD obtained acutely with GPe-
DBS are in general not sustained. Similarly, the effects of GPi-DBS on the off medication 
symptoms of PD, can evolve over short periods of time presumably as a result of changes in 
network-wide neuronal plasticity. These clinical observations provide further insight into DBS 
mechanism of action, and can also help inform optimal methods of GPi-DBS programming. 
 
Introduction 
Deep brain stimulation (DBS) of the Globus Pallidus pars interna (GPi) is a recognised 
treatment for patients with Parkinson’s disease (PD) [1]. The original pioneers of this surgery 
in Zurich, Switzerland [2] then in Grenoble, France [3], observed and reported the beneficial 
effects of chronic GPi DBS for the long-term amelioration of L-dopa induced dyskinesia 
(LID). These antidyskinetic effects of GPi DBS have been shown to persist for greater than 5 
years [4]. In parallel, GPi DBS has been found to be helpful in a range of other hyperkinetic 
movement disorders including Dystonia, Huntington’s chorea and Tourette’s syndrome 
[5,6,7]. 
 
The role of GPi DBS in the treatment of hypokinetic signs i.e. akinesia, rigidity and tremor 
has also been studied. Early series of patients undergoing GPi DBS reported conflicting 
results [2,8], and subsequent open label series have also shown markedly variable 
improvements in UPDRS 3 off-medication scores: 10% [9], 39% [10] and 54% [11], with the 
latter studies suggesting beneficial effects on rigidity, akinesia, tremor and axial signs 
persisting for at least 12 months. Nevertheless, patients tend to be able to make only small 
reductions in L-dopa equivalent dose as compared to patients undergoing subthalamic 
nucleus (STN) DBS. More recently, the efficacy of GPi DBS in relieving the motor symptoms 
of PD (as measured by the UPDRS part 3) has been the subject of several randomised 
controlled trials. In comparisons over 12-24 month periods, patients randomised to GPi DBS 
had improvements in UPDRS part 3 off medication scores of 26- 29% [12,13], which, 
although equivalent to the improvement seen with STN DBS in the only randomised study 
using UPDRS part 3 as the primary outcome measure [12], is lower than that reported with 
STN DBS in several other studies [13,14,15,16]. 
 
The globus pallidus is substantially larger than the STN, which perhaps explains some of the 
variable/contrasting effects seen. Following a series of acute experiments comparing the 
effects of stimulation through different contacts on a GP electrode, the Paris group [17], then 
the Grenoble group [3] reported that stimulation of the ventral pallidum (GPi) could alleviate 
rigidity but at the same time blocked the anti-akinetic effect of levodopa, while stimulation of 
the dorsal GPi or Globus Pallidus pars externa (GPe) alleviated akinesia, and induced 
dyskinesia but had little or no effect on rigidity. They concluded that these effects are 
mediated through stimulation of either pallidofugal fibres from cells in the lateral GPi forming 
the ansa lenticularis, in contrast to the effects of stimulation of cells in medial GPi which form 
the lenticular fasciculus, these pathways terminating in different thalamic subnuclei. They 
suggested activation of intermediate contacts on a GP electrode for a beneficial compromise 
between these effects [3].  
 
Similarly, in other series of patients with GPi DBS studied in the acute setting, it appeared 
that ventral GPi stimulation improved dyskinesia but worsened akinesia, while GPe DBS 
relieved akinesia but provoked dyskinesia. Stimulation of either target improved rigidity 
[18,19].  
 
It has also been observed that chronic ventral GPi DBS can provoke features of 
parkinsonism in patients with cervical dystonia [20].  Furthermore, the effects of GPi DBS in 
patients with dystonia are known to evolve over days, weeks or even months suggesting 
downstream effects on synaptic plasticity as one mechanism of action of this therapy. The 
beneficial effects of GPi DBS in PD are therefore somewhat nuanced and clearly depend on 
the exact anatomical position of the contact delivering the stimulation as well as the 
timepoint at which the effects are observed.  
 
While the acute and chronic benefits of posteroventral GPi DBS for L-dopa induced 
dyskinesia are no longer a subject of debate, differences between acute and longer lasting 
effects of stimulating dorsal sub-regions of the globus pallidus (GP) have not been 
comprehensively studied. This issue has clinical relevance not only for surgical targeting but 
also to help advise clinicians responsible for DBS programming and deriving conclusions 
regarding optimal stimulation parameters. Acute effects may be profoundly different from 
effects of prolonged stimulation over subsequent weeks or months. In this study, the aim 
was to systematically explore the effects of stimulation delivery to different regions of the GP 
in patients with chronically implanted electrodes, both acutely and over a 6 and 12 week 
follow up period. These data were used to inform not only on the consistency and longevity 
of DBS related effects, but also to ensure that every patient was receiving the optimal 
stimulation parameters taking into account both OFF motor symptoms and signs, as well as 
Levodopa induced dyskinesias.  
 
Methods 
Patients  
All participants were patients with PD who had undergone bilateral GPi DBS and were under 
long term follow up at the National Hospital for Neurology & Neurosurgery, Queen Square, 
London. All patients had undergone GPi DBS surgery with the primary aim of ameliorating 
their disabling levodopa-induced dyskinesia (LID).  For the purposes of this study, all 
adjustments to DBS parameters were performed to improve the clinical status of the 
patients. In the absence of clinical improvement, DBS parameters were reset to previously 
optimised settings. As such, and after informal discussions, research ethics approval was 
not considered necessary. 
 
DBS Surgery 
All DBS Surgeries were performed between 2003 and 2011 using a standard operative 
technique carried out by 1 or 2 functional neurosurgeons that has been described in detail 
previously, with emphasis on stereotactic MRI-guided and stereotactic MRI-verified electrode 
placement to minimise the number of brain penetrations while ensuring targeting accuracy 
[21,22,23,24,25]. All patients were implanted with bilateral 3389 DBS electrodes (Medtronic, 
Minneapolis) connected to either a Kinetra or Activa PC Implantable Pulse Generator (IPG). 
Using a surgical trajectory to avoid the lateral ventricle, all our electrodes targeted to GPi, 
pass through the GPe, resulting in the most inferior contacts of the electrodes lying in the 
ventral GPi, whereas the most superior contacts lie in the border of GPi- GPe (laminar zone) 
or in the superior and posterior part of GPe. (Supplementary Figure) 
 
All patients underwent a stereotactic MRI scan immediately after lead implantation, for 
verification of precise anatomical lead positioning prior to connection to the IPG. Post-
operative programming had been previously performed in the On medication state, and had 
satisfactorily ameliorated levodopa induced dyskinesia (LID) which had been the primary 
indication for surgery.  
 
Patient assessments  
The purpose of this study was to ensure that a cohort of patients already receiving chronic 
GPi DBS as a treatment for PD dyskinesia were receiving optimal stimulation parameters, as 
judged in both the OFF medication and ON medication condition, rather than solely focusing 
on severity of dyskinesia. Patient assessments were performed in 3 formal sessions of 
stimulation adjustment each separated by 6 weeks. 
 
Baseline Assessment 
All patients attended after an overnight cessation of medications. All patients underwent a 
systematic motor evaluation, in four states in a consistent sequence: 1) Off medication - ON 
ventral GPi i.e. DBS through inferior contacts previously used to control LID, 2) Off-
medication - ON GPe DBS i.e. through superior contacts (verified on post operative imaging 
to lie in the GPe/ laminar region- for the purpose of this manuscript these will be referred to 
as GPe DBS) 3) Off-medication - ON combined GPi-GPe i.e. DBS through combined inferior 
and superior contacts, 4) On-medication - ON "optimal" DBS. All assessments throughout 
the study were performed using a fixed pulse width of 60us and a frequency of 130Hz. At 
each setting, changes to the stimulation amplitude were titrated against the degree of 
symptom control and development of side effects. 
  
Motor evaluations were performed using Part 3 of the Unified Parkinson’s disease rating 
scale (UPDRS). At least five to ten minutes was allowed to elapse following each change in 
DBS parameters before motor evaluations were performed.  At the end of the assessment, 
the "optimal" stimulation parameters were selected for each patient taking into account the 
objective motor evaluation in both the presence and absence of medication, the occurrence 
of side effects (in particular dyskinesia) and the patient’s own “subjective” views. At the end 
of each session, patients returned home with their new “optimal” DBS setting. 
 
Follow-up Assessments 
Each patient that had an objective benefit from changing DBS parameters was invited to 
return for a repeat assessment at 6 weeks after an overnight period Off medication, and 
were evaluated 1) Off medication - ON newly derived “optimal” DBS parameters, followed by 
2) Off medication - ON original GPi DBS setting and 3) On medication - ON "optimal" 
stimulation parameters. The same procedure was repeated at 12 weeks in those patients 
who had persisted with a new setting compared with their baseline DBS parameters.  
 
Statistical Analysis 
All statistical tests were performed using Stata version 8. Data were checked for normality 
using Shapiro-Wilk test. For normally distributed variables, paired t-tests were used to 
compare scores noted with different DBS parameters. For non-normally distributed 
variables, Wilcoxon signed rank tests were used. 
 
Results  
Patient Data 
Thirteen PD patients (9 male) with chronically implanted GPi electrodes agreed to participate 
in this study. Their mean age at onset was 45.5 (range 24-58), mean disease duration of 
18.9 years (range 9-39 years), and duration since GPi DBS surgery was 3.6 years (range 1-
9 years). No patients received adjustment to their medication regime during this period of 
study. 
 
Contact positions 
Post-operative stereotactic MRI sequences confirmed that the inferior contacts on each 
electrode were anatomically situated in the GPi, while the superior contacts of each 
electrode were in the GPe and/or laminar zone between GPi and GPe (for example see 
Supplementary Figure). 
 
Off medication baseline assessment:  
Effects of GPi DBS and acute GPe DBS – OFF medication 
The sequence of assessments throughout the study is presented in Figure 1. At baseline, 
the mean Off medication - ON GPi UPDRS part 3 score was 50.2 (SD 8.1). In the Off 
medication - ON GPe state, this score fell to 41.1 (SD 11.4) (p =0.003) (Fig 2). The individual 
UPDRS scores and stimulation parameters are presented in Table 1.  11/13 patients had 
better part 3 scores ON GPe DBS than ON GPi DBS. Comparison of the UPDRS part 3 sub-
scores of akinesia, rigidity, tremor and axial symptoms all favoured GPe stimulation 
(p<0.05). 
 
In the Off medication - ON GPe DBS state, (hyperkinetic) dyskinesia or dystonia was 
observed in nine patients. This resembled L-dopa induced dyskinesia and was aggravated 
by increases in amplitude of GPe stimulation. Three patients described numbness 
contralateral to stimulation site, dizziness and an unpleasant feeling closely related to 
increasing stimulation amplitude. During these assessments eight out of the thirteen patients 
also reported a “subjective” improvement in their function in the Off medication - ON GPe 
DBS state in comparison to the Off medication - ON GPi DBS state, while five patients 
perceived no functional difference between these two states. 
 
Combination of GPi & GPe DBS 
In the Off medication - ON GPi-GPe DBS condition, mean UPDRS part 3 total score was 
35.3 (SD 10.2), representing a further improvement compared with GPe HFS (Mean 
difference 5.1 points, p =0.01).  One patient did not undergo this evaluation because of 
fatigue. Off medication dyskinesia/dystonia was completely eliminated by the acute 
combination of inferior (GPi DBS) and superior (GPe DBS) contacts with preservation of the 
benefits noticed in the ON GPe DBS state. The eight patients that experienced a beneficial 
response ON GPe DBS continued to report a subjective beneficial response on the ON GPi-
GPe DBS state as well. 
 
ON Medication ON GPi-GPe  
Further small improvements in mean UPDRS part 3 score were seen with medication (mean 
30.6 (SD 12.1). None of the patients had LIDs using the combined GPi-GPe DBS setting. 
The eight patients with both an objective and subjective sense of PD improvement chose to 
maintain their new DBS settings and agreed to attend a follow up visit at 6 weeks. 
 
Follow up assessment at 6 weeks 
One patient did not manage to attend the 6-week follow up assessment for personal reasons 
but attended the 12 weeks time point. In the other seven patients, in the off medication state, 
there was still a significant advantage of GPi-GPe DBS in comparison to GPi DBS (p=0.02); 
although this was less compared with the corresponding baseline GPi-GPe DBS 
assessment (p=0.01) (Table 3). 
 
Four of these patients reported a subjective gradual loss of the initial benefit from the change 
to combined GPi-GPe DBS. These patients were switched back to their original GPi DBS 
setting, and an On-medication ON GPi DBS evaluation performed. 
 
Follow up Assessment at 12 weeks 
The four patients still persisting with the GPi-GPe DBS setting were evaluated having 
completed 12 weeks of combined GPi-GPe DBS. In all of these individuals there was now an 
advantage of using GPi DBS alone compared with the combined GPi-GPe DBS. All four 
patients were therefore switched back to their original GPi DBS settings and an On-
medication - ON GPi assessment performed. 
 
Comparing UPDRS part 3 scores in the Off-medication - ON GPi-GPe DBS state between 
baseline and the time point of exit from the study (4 patients at 6 weeks and 4 patients at 12 
weeks) showed a significant decline of acute GPi-GPe DBS effectiveness. In contrast, there 
was significant improvement of UPDRS part 3 with GPi -DBS in comparison with the same 
setting at baseline (p=0.006). 
 
Discussion 
In this study, we have explored the acute and short-term effects of DBS through different 
parts of the GP in an attempt to improve the symptom control of patients already receiving 
chronic GPi DBS as a treatment for LID. Acute changes in stimulation through superior 
contacts lying within the GPe had consistent beneficial effects on akinesia and rigidity 
although at the expense of provoking off-medication dyskinesia. Combining stimulation 
through both GPi and GPe contacts resulted in the best control of akinesia and rigidity, 
without dyskinesia, in both Off and On-medication states in the acute setting, but with short 
term follow up, this did not lead to sustained advantages over GPi DBS alone. Of particular 
interest was the observation that reinstating GPi DBS alone after an interval of combined 
GPi-GPe DBS had greater impact on Off-medication signs than that seen with previous 
chronic GPi DBS at the same settings. 
 
The change in therapeutic response to GPi DBS, suggests that the intervening period during 
which patients received combined GPi & GPe DBS might have had neuromodulatory effects 
on the basal ganglia motor network, perhaps mediated via changes in synaptic plasticity i.e. 
long term potentiation/depression. A previous non-human primate study has similarly 
suggested that therapeutic effects on parkinsonism may not be immediate following GPi 
DBS, and indeed may be preceded by a period of aggravated symptoms, although in this 
study observations occurred over minutes rather than weeks [26]. Pallidotomy studies in the 
same primate models have shown that lesions in the GPe exacerbate parkinsonism [27], 
further distinguishing the mechanism of action of GPe DBS which appear to be mediated 
through neuronal activation rather than suppression [26, 28]. This is also supported by case 
reports where human patients with a pallidotomy in the GPe had either worsened or had no 
beneficial effect, requiring a re-operation with a new pallidotomy into the GPi [29,30] 
 
Explanations of DBS mechanisms, based purely in terms of stimulating/inhibiting the rate or 
pattern of firing in 1) orthodromic GPi- thalamic pathway, 2) antidromic striatum- GPi “direct 
pathway” or 3) antidromic STN-GPi pathway are likely to be over-simplistic. Whole network 
based changes occur as a result of STN DBS as has been demonstrated using resting state 
fMRI and measuring effective connectivity using stochastic dynamic causal modelling [31]. It 
is thus tempting to speculate that similar network based changes occur over time with GPi 
DBS and thus explain the variable clinical responses seen over time.  
 
The acute effects of GPe DBS were more reminiscent of those seen with acute STN DBS 
i.e. a major reduction of akinesia and rigidity, accompanied by an increase in dyskinesia. 
The GPe is highly connected to the STN, and acute effects of GPe stimulation may be 
mediated via a change in the synchronized oscillatory beta activity in the GPe-STN 
projection. However, given that the clear clinical effects of GPe DBS do not appear to be 
sustained, one possible explanation is that the orthodromic influence of GPe DBS on STN 
activity is unable to impact to the same extent on network-wide effective connectivity 
changes seen in the direct and hyperdirect pathways associated with STN stimulation [31].  
 
The current study has several limitations. The number of patients included was inevitably 
limited by the small number of patients undergoing GPi DBS in our centre in comparison to 
STN DBS. In addition, the aim of the study was to ensure that all patients received optimal 
symptom control using combined GP DBS and medications throughout, therefore patients 
wishes were kept paramount and patients were not compelled to complete OFF stimulation 
assessments. Those experiencing negative effects or loss of efficacy, were able to switch 
back to former settings at either the 6 or 12 week stage introducing variability in the results. 
Furthermore, settings were chosen without the clinical assessor, nor the patient being 
blinded to stimulation parameters, which is a potential source of bias. A further limitation is 
that the patients’ original “GPi” settings were not homogeneous and included any GPi 
contacts 0-, 1-, or 2- for either electrode although no patients were receiving stimulation 
through the most superior GPe contacts (3-) at baseline, while all were stimulated through 
the most superior contacts (3-) throughout the “GPe” study period. Given that we used a 
fixed pulse width and frequency throughout the study, we cannot extrapolate our results to 
patients receiving other stimulation parameters.  
 
Despite the marked benefits seen with acute combined GPi-GPe DBS, all patients 
experienced a gradual loss of the initial beneficial effect, with the result that at the end of the 
study period, all patients preferred to pursue with GPi DBS alone. These observations are 
important not only in helping our understanding of the role of the GPi/ GPe in PD 
pathophysiology, and its manipulation by DBS, but also on a practical level, i.e. programming 
of individual patients. It is tempting to speculate that the beneficial effects of GPe DBS might 
be prolonged or even enhanced by an adaptive DBS type setting i.e. using a closed loop 
system to detect abnormal patterns of brain activity and delivering stimulation accordingly 
[32]. However the slower and varied clinical responses seen using GPi DBS, especially as a 
treatment for LID, may remain a challenge even for adaptive DBS systems.  
 
Ultimately, we conclude that patients selected for GPi DBS in view of severe troublesome 
dyskinesia, considered unsuitable for STN DBS in view of borderline cognition or speech, 
receive substantial benefit for their LIDs from combined stimulation and medication.  
However, while attempting to make further improvements in “OFF” period fluctuations in this 
group of patients through stimulation adjustment is tempting, especially in patients with 
limited alternative treatment options, this study suggests that acute beneficial effects 
associated with stimulation through the dorsal contacts may not be sustained. 
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Legend to Figures: 
Supplementary Figure. 
a) Wire mesh 3D figure of 3389 DBS lead lying within the posterior GPi and GPe. Software 
used to create figure courtesy of Dr Mattias Astrom. b) Stereotactic proton density MRI: axial 
view of (i) inferior and (ii) superior active contacts within the ventral GPi and dorsal GPe 
respectively and (iii) coronal view.  
FIG 1. 
Flow chart of patient assessments throughout the study. 
 
FIG 2. 
Graphical comparison of UPDRS part 3 OFF medication scores on different DBS stimulation 
parameters at baseline and at study exit. 
